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Volume 59, Number 6S Abstracts 79Sdeep venous thrombosis (DVT) or pulmonary embolism
(PE). Inferior vena cava (IVC) ﬁlter was placed in eight.
In group 1, 17 limbs were treated with OST (ligation
and stripping/excision of saphenous or lateral embryonic
veins); in group 2, 10 limbs were treated with RFA. Phle-
bectomies were performed in both groups, with thigh
tourniquet in 21 limbs. Technical success of saphenous/
lateral vein ablation was 100% in group 1 and 90% in
group 2. There was no DVT or PE; none had thrombus
extension into deep veins after RFA. Perioperative compli-
cations occurred in 19% (three of 16) in group 1
(bleeding, wound dehiscence, paresthesia) and in 20%
(two of 10, P ¼ NS) in group 2 (bleeding, thrombophle-
bitis). Follow-up averaged 15 months (range, 1-57
months). No patients reported worsening of symptoms,
and none required repeat interventions. Marked improve-
ment in symptoms was reported in 55% in group 1 and in
25% in group 2 (P ¼ NS). All patients continued to wear
elastic garments.
Conclusions: Surgical and endovenous treatment in
select patients with KTS is safe and can be performed
with low rate of complications. More data are needed
to justify IVC ﬁlter placement. Although symptomatic
varicose veins can be removed, residual symptoms due
to persistent venous insufﬁciency are frequent. Lifelong
elastic support is warranted.
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Objectives: Inferior vena cava (IVC) ﬁlter placement
is not without risk. It has been associated with puncture
site bleeding, venous thrombosis, as well as ﬁlter migra-
tion and perforation. The objective of this study was to
assess our experience with open operative explantation
of IVC ﬁlters.
Methods: After IRB approval, patients were identiﬁed
from case logs that had transabdominal IVC ﬁlter removal
between 1994 and 2013. Patient demographics, thrombo-
embolic risk proﬁle, clinical history, operative indication,
and outcomes were recorded for each case.
Results: Eighteen patients (9 male; mean age, 49.6
years) were identiﬁed. IVC ﬁlters (4 permanent, 8 retriev-
able, 6 unknown) were deployed for a combination of
signiﬁcant thromboembolic events (n ¼ 16), after trauma
(n ¼ 3), or after failure of anticoagulation therapy
(n ¼ 2). Ten patients had retrievable ﬁlters that were
not removed percutaneously due to ﬁlter strut perforation
into surrounding pericaval tissue. Seven patients subse-
quently presented with abdominal/back pain, hematuria,
or sepsis. Midline laparotomy was used for explantation in11 patients during oncologic resections. A subcostal inci-
sion (n ¼ 5) was used for planned explantation alone.
One patient had robotic-assisted laparoscopic removal
and another had an open transjugular removal. Caval
venotomy was primarily closed (n ¼ 15) or patched
with bovine pericardium (n ¼ 2). No complications
attributed to ﬁlter removal were identiﬁed in the postop-
erative period. One patient died of advanced malignancy,
and the other 17 patients remain well (mean follow-up,
618 days).
Conclusions: Filter strut caval perforation remains
the most signiﬁcant indication for transabdominal removal.
Filter removal is often considered incidentally during onco-
logic resection. Although operative explantation still remains
infrequent, our series suggests that it may be performed
safely without signiﬁcant postoperative complications.
Author Disclosures: T. C. Bower: Nothing to disclose;
R. J. Fowl: Nothing to disclose; P. Gloviczki: Nothing
to disclose; S. R. Money: Nothing to disclose; M. E.
O’Donnell: Nothing to disclose; W. M. Stone: Nothing
to disclose.
PS192.
Endovascular Venous Ablation in the Setting of
Warfarin Anticoagulation: Experience at a Single-
Center Institution
Victoria Lee1, Jonathan Ekstroem2, Glenn R. Jacobowitz1.
1Surgery, NYU Medical Center, New York, NY; 2Rutgers
University, Newark, NJ
Objectives: To determine the difference in durability
of venous ablation in patients on warfarin anticoagulation
compared with those without alteration in their coagula-
tion pathway.
Methods: Data were collected from a single-center
institution: NYU Medical Center using International
Classiﬁcation of Diseases, Ninth Revision codes for pa-
tients who had undergone radiofrequency or laser venous
ablation between April 2011 and May 2013. Covidian
CF7-7-60 2nd generation VNUS catheters were used
for radiofrequency ablation and EVLT NeverTouch kits
by Angiodynamics for laser ablation. Patients being
concomitantly treated with warfarin were selected for
study. Follow-up with venous duplex ultrasound imaging
was performed at 1 week, 6 months, and then yearly to
check for thrombus extension from the superﬁcial to
the deep venous system and document occlusion status
of the treated veins.
Results: There were 72 patients: 40 male (55.5%) and
32 female (44.5%), with 94 limbs and 97 procedures per-
formed. Average follow-up time was 142.5 days (range,
7-636 days). Fifty-four procedures (55.7%) were radiofre-
quency ablations, and 43 (44.3%) were laser ablations.
Four veins (4.1%) recanalized within the follow-up time
period: one was a radiofrequency ablation (1.9%), and
three were laser (7.0%). Two of these occurred #1 week,
and the other two between 6 and 12 months after the pro-
cedure. Nine patients (12.5%) in our study were on aspirin
and one (1.3%) was on Plavix, all of whom had successful
venous ablations without recanalization within the
follow-up time period. None of the patients in our study
experienced complications.
